HKTDC Hong Kong Means Business

Hong Kong Means Business Hong Kong Means Business
  • Login / Register

Languages

  • EN
  • 繁
  • 简
SUBSCRIBE
  • EVENTS
  • MY FEED
  • CONTACT HKTDC
  • ABOUT HKTDC
  • hktdc.com

Section Menu

  • multimedia
  • market spotlight
  • first person
  • Venture Hong Kong
  • heads-up
  • inside china
  • life & style
  • hktdc research
  • Login / Register

Languages

  • EN
  • 繁
  • 简
SUBSCRIBE
Hong Kong Means Business

Section Menu

  • multimedia
  • market spotlight
  • first person
  • Venture Hong Kong
  • heads-up
  • inside china
  • life & style
  • hktdc research

https://hkmb.hktdc.com/en/1X0ALAWA

market spotlight
SAVE FOR LATER
SHARE / SEND

"Scan QR Code" in WeChat and tap "..." to share.

Pharmaceutical pioneer seeks HK talent

AstraZeneca links up with a Hong Kong technology park to develop new cancer diagnostics and treatments.

23 February 2021

Gwenael Meneux
Gwenael Meneux, General Manager of AstraZeneca Hong Kong and Macao

Hong Kong is Asia’s biggest fund-raising hub for biotechnology, and the world’s second-largest, behind the United States’ Nasdaq. The city would become the world’s number one between 2025 and 2030, according to predictions made last September by the then Chief Executive of the Hong Kong Exchanges and Clearing (HKEX), Charles Li.
The city’s biotech rush is partly attributable to authorities’ relaxation of rules allowing pre-profit companies to list on HKEX boards but the thriving community of biotech start-ups in the city plays no small role.

Incubator


Noting this potential, United Kingdom-Swedish research-based pharmaceutical firm AstraZeneca and the Hong Kong Science and Technology Parks Corporation (HKSTP or HKSTPC) launched a co-incubation programme this month to support biomedical start-ups in their mission to develop integrated cancer treatment solutions to accelerate innovation in oncology, foster biomedical technologies in Hong Kong and enhance the city’s status as a leading biomedical innovation hub.
In the past decade, malignant cancerous tumours had been the number-one cause of death among all diseases in Hong Kong, according to Astrazeneca.

Alfred Sit
Alfred Sit, Secretary for Innovation and Technology of the Hong Kong Special Administrative Region

"Today’s cancer treatment solutions, physical check-ups, diagnosis, treatment, follow-up and rehabilitation, are all interrelated. Improvements in either aspect of the patient journey will create huge opportunities to drive better treatment outcomes," Astrazeneca said in a statement .

R&D boost

The programme will attract local and overseas start-ups to embed themselves in the Science Park and develop comprehensive oncology diagnosis and treatment solutions. Successful programme applicants will qualify for professional support from HKSTP, including funding support of as much as HK$6 million, working space and advanced laboratory facilities, as well as access to HKSTP’s value-added services platform which provides business matching opportunities with strategic partners and potential investors, and talent support.
In the programme, AstraZeneca will back start-ups and help link them to industry stakeholders and partners, so they can better understand industry information and related opportunities. AstraZeneca will also leverage existing networks with mainland and global markets, including the Wuxi International Life Science Innovation Campus (I·Campus) co-built with local government and Emerging Markets Health Innovation Hubs, SLUSH and Cambridge Network, to provide platforms for exploring opportunities overseas.
The plan will last for two years. Participating start-ups will also become members of HKSTP’s Incu-Bio programme incubating biotech start-ups.
“We look forward to our first collaboration with HKSTP, which hopefully will create a vibrant medical ecosystem,” Gwenael Meneux, General Manager of AstraZeneca Hong Kong and Macao, said at the HKSTP-AstraZeneca Co-Incubation Programme Collaboration Agreement Signing Ceremony on 9 February .
HKSTP CEO Albert Wong said: “With the professional knowledge, rich industry experience and global cooperation network from AstraZeneca, together with our world-class infrastructure and support, we will be able to attract high potential start-ups to land in Hong Kong, accelerate their growth, bring widespread benefit to cancer patients, and establish Hong Kong as a global leader in biomedical innovation.”

Oncology partnership project

The ceremony was also attended by Alfred Sit, Hong Kong Special Administrative Region Secretary for Innovation and Technology, who hailed the collaboration as “a great leap” in the biotech field of the local ecosystem, creating a unique "one-stop solution integration platform" for the whole course of action in combating cancer from diagnosis.
“The hands-on experience and extensive networks of AstraZeneca coming together with the state-of-the-art incubation support of HKSTPC will complement the strengths of each other in facilitating the development of biotech start-ups. Hopefully, these start-ups will excel in technical and business knowledge under AstraZeneca's mentorship and in solution development with HKSTPC's incubation support,” Mr Sit said.
“We firmly believe in nurturing a vibrant innovation and technology ecosystem for start-ups and talents to thrive. In this regard, we have committed over HK$100 billion [US$12.9 billion] to support the I&T (innovation and technology) development in Hong Kong in eight major areas,” he added.
“One area showcasing the software aspect of the government support is to enhance the local research capabilities and build the city into a hub for global research collaborations,” he said.
A major government initiative to develop Hong Kong as the hub for global research collaboration is InnoHK, which involves the establishment of world-class research clusters at HKSTP’s Hong Kong Science Park featuring research laboratories set up by world renowned institutions and/or commercial entities to conduct collaborative research.
“Two InnoHK research clusters, one on healthcare technologies and the other on artificial intelligence and robotics technologies, are being set up at the Science Park for pulling together world-class institutes and scientists,” noted Mr Sit.
“As the world's second-largest biotech fundraising hub, Hong Kong provides lots of resources and opportunities for biotech businesses to prosper.”
Related links
Astrazeneca
HKSTP Incu-Bio

BACK TO TOP ^
CONTENT PROVIDED BY
    Topics:
  • Medical Supplies & Medicine,
  • Finance & Investment,
  • Hong Kong,
  • Biotech,
  • MedTech,
  • start-ups
  • Medical Supplies & Medicine
  • Finance & Investment
  • Hong Kong
Home

Article Topics

ARTICLE TOPICS

MEDICAL SUPPLIES...24721
FINANCE & INVESTMENT24664
HONG KONG36026
BIOTECH119043
MEDTECH141964

ARTICLE TOPICS

MEDICAL SUPPLIES & MEDICINE24721
FINANCE & INVESTMENT24664
HONG KONG36026
BIOTECH119043
MEDTECH141964
START-UPS98715

Innovation terms banner block

Social Share

FOLLOW US

GET WEEKLY UPDATES

newpaper-img

GET OUR WEEKLY EMAIL UPDATES

banner-img


I acknowledge that the above information may be used by the Hong Kong Trade Development Council (HKTDC) for incorporation in all or any of its database for direct marketing or business matching purpose (and may therefore become available to the public within and/or outside of Hong Kong for use by them), and for any other purposes as stated in the Privacy Policy Statement; I confirm that I have the consent and the authority of each individual named in this form to release their personal data for the purposes stated herein.


*For non-EU/EEA customers, please skip this box which is solely for EU/EEA customers as required by the relevant data protection law in the EU.

THANK YOU

Thank you for registering.

interest_article

YOU MAY BE INTERESTED IN

22 March 2021

Navigating Covid-19: An AI-Integrated Pharmacist

08 March 2021

Biden Administration Defends Trump’s Ban on U.S. Securities Transactions by Mainland Chinese Entities

03 March 2021

INDONESIA: New Positive List Expands Overseas Investment Sectors

02 March 2021

Supply Chain Review Could Yield Pressure for Sourcing Shifts

Related Events

RELATED EVENTS

12 - 13 August 2021

International Conference of the Modernization of Chinese Medicine & Health Products 2021

13 - 16 October 2021

HKTDC Hong Kong International Medical and Healthcare Fair 2021

27 - 30 October 2021

Eco Expo Asia 2021

28 - 31 March 2022

Hong Kong Pavilion at FHA–Food & Beverage, Singapore
FIND AN EVENT

User login

  • Create new account
  • Request new password

Footer Menu

  • hktdc.com
  • ABOUT HKTDC
  • MEDIA ROOM
  • TERMS OF USE
  • PRIVACY POLICY
  • SITEMAP
  • 京ICP备09059244号

Footer Logo

Copyrights

Copyright © 2021 Hong Kong Trade Development Council. All rights reserved.

SHARE THIS STORY

EMAIL
LINKEDIN
WeChat
FACEBOOK
TWITTER
WHATSAPP

ID: HKTDCofficial

Don't have an account?

Create An Account

successfully added on your preferences.